The effectiveness of anti-IgE therapy for allergic rhinitis in patients with severe atopic bronchial asthma and concomitant allergic rhinitis in real clinical practice
- Authors: Kiseleva D.V.1, Beltyukov E.K.1, Naumova V.V.1
-
Affiliations:
- Ural State Medical University
- Issue: Vol 19, No 3 (2022)
- Pages: 289-298
- Section: Original studies
- Submitted: 05.04.2022
- Accepted: 11.07.2022
- Published: 07.10.2022
- URL: https://rusalljournal.ru/raj/article/view/1533
- DOI: https://doi.org/10.36691/RJA1533
- ID: 1533
Cite item
Abstract
BACKGROUND: Omalizumab, by binding immunoglobulin (Ig) E in patients with atopic asthma, can improve clinical and functional parameters and patients’ quality of life.
AIM: To evaluate the efficacy of anti-IgE therapy in patients with allergic rhinitis treated with omalizumab for concomitant severe atopic asthma in real clinical practice
MATERIALS AND METHODS: This open, non-interventional, prospective, and non-randomized study in real clinical practice was conducted in the Sverdlovsk region in October 2021 based on a regional registry of adult patients with severe asthma with chronic nasal inflammatory diseases and receiving targeted therapy. Dynamics of nasal symptoms were assessed using the Sino-nasal-outcome test 22 (SNOT-22) questionnaire and visual analog scale (VAS) initially and after 4 and 12 months of omalizumab therapy. Peripheral blood eosinophil level was assessed before and after 4 months of omalizumab therapy.
RESULTS: The study included 26 patients. Assessment of nasal symptoms dynamics using the SNOT-22 questionnaire at baseline and after 4 months of omalizumab therapy revealed a decreased severity of symptoms (p <0.001) of 46.85±22.04 points at baseline (95% confidence interval [CI]: 37.94–55.75) and 30.65±14.81 points after 4 months (95% CI: 24.67–36.64). Additionally, improvement in SNOT-22 questionnaire score was revealed in 18 patients treated with omalizumab during 12 months, with 47.5 points before therapy (Q₁–Q₃: 35.7–59.3), 30.4 points after 4 months (Q₁–Q₃: 22.1–38.1), and 24.9 points after 12 months (Q₁–Q₃: 16.9–32.9) (p=0.001). Improvement in rhinitis symptoms control was observed according to the VAS scale, with 8.0 points before therapy (Q₁–Q₃: 6.2–9.0), 5.0 points after 4 months (Q₁–Q₃: 3.2–5.8), and 5.0 points after 12 months of treatment (Q₁–Q₃: 4.0–6.8). The eosinophil levels (n=16) decreased from 510.9±317.9 cells/µl (95% CI: 341.5–680.3) to 327.4±217.7 cells/µl (95% CI: 211.4–443.5) after 4 months of anti-IgE therapy (p <0.041).
CONCLUSIONS: Omalizumab in real clinical practice has demonstrated improvement of rhinitis symptoms and quality of life in patients with allergic rhinitis with concomitant severe atopic asthma. Additionally, a statistically significant decrease in peripheral blood eosinophils level was observed, which largely determines airway inflammation severity and clinical manifestations of allergic rhinitis and bronchial asthma.
Keywords
Full Text
![Restricted Access](https://rusalljournal.ru/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Darina V. Kiseleva
Ural State Medical University
Author for correspondence.
Email: darinakiseljova@mail.ru
ORCID iD: 0000-0002-7847-5415
SPIN-code: 9446-7866
ResearcherId: AGI-2417-2022
MD
Russian Federation, EkaterinburgEvgeny K. Beltyukov
Ural State Medical University
Email: asthma@mail.ru
ORCID iD: 0000-0003-2485-2243
SPIN-code: 6987-1057
Scopus Author ID: 6504558662
ResearcherId: AAI-1608-2020
MD, Dr. Sci. (Med.), Professor
Russian Federation, EkaterinburgVeronika V. Naumova
Ural State Medical University
Email: nika.naumova@gmail.com
ORCID iD: 0000-0002-3028-2657
SPIN-code: 8210-6478
ResearcherId: AAI-1588-2020
MD, Cand. Sci. (Med.)
Russian Federation, EkaterinburgReferences
- Astafieva NG, Baranov AA, Vishneva EA, et al. Allergic rhinitis. Russ Rhinology. 2020;28(4):246–256. (In Russ). doi: 10.17116/rosrino202028041246
- Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S103–S115. doi: 10.1016/j.jaci.2009.12.989
- Emelyanov AV, Ilina NI, Karneeva OV, et al. Unresolved issues of management of patients with severe allergic rhinitis and nasal polyposis. The possibilities of anti-IgE therapy. Russ Otorhinolaryngology. 2020;19(3):88–99. (In Russ). doi: 10.18692/1810-4800-2020-3-88-99
- Vlaykov A, Vicheva D, Dimov P, Stoyanov V. Assessment of quality of life in patients with allergic rhinitis. Russ Rhinology. 2016;24(1):38–42. (In Russ). doi: 10.17116/rosrino201624138-42
- Gaudin RA, Hoehle LP, Birkelbach MA, et al. Assoziation zwischen kontrolle der allergischen rhinitis und schlafqualität. HNO. 2017;65(12):987–992. doi: 10.1007/s00106-017-0398-9
- Hoehle LP, Speth MM, Phillips KM, et al. Association between symptoms of allergic rhinitis with decreased general health-related quality of life. Am J Rhinol Allergy. 2017;31(4):235–239. doi: 10.2500/ajra.2017.31.4444
- Mahdavinia M, Schleimer RP, Keshavarzian A. Sleep disruption in chronic rhinosinusitis. Expert Rev Anti Infect Ther. 2017;15(5): 457–465. doi: 10.1080/14787210.2017.1294063
- Speth MM, Hoehle L, Phillips KM, et al. Treatment history and association between allergic rhinitis symptoms and quality of life. J Med Sci. 2019;188(2):703–710. doi: 10.1007/s11845-018-1866-2
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Res J. 2013;43(2):343–373. doi: 10.1183/09031936.00202013
- Global Initiative for Asthma. Global strategy for asthma management and prevention, updated 2018. Available from: http://www.ginasthma.org. Accessed: 15.01.2022.
- Global Initiative for Asthma. Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. V. 2.0, April 2019. Available from: http://www.ginasthma.org. Accessed: 15.01.2022.
- Allergic rhinitis. Clinical recommendations. The Russian Association of Allergology and Clinical Immunology; 2018. (In Russ). Available from: https://nrcii.ru/docs/2.allergic_rhinitis.pdf. Accessed: 15.01.2022.
- Allergic rhinitis. Clinical recommendations. The Russian Association of Allergology and Clinical Immunology, National Medical Association of Otorhinolaryngologists, The Union of Pediatricians of Russia; 2020. (In Russ). Available from: https://cr.minzdrav.gov.ru/recomend/261_1. Accessed: 15.01.2022.
- Mozzanica F, Preti A, Gera R, et al. Cross-cultural adaptation and validation of the SNOT-22 into Italian. Eur Arch Otorhinolaryngol. 2017;274 (2):887–895. doi: 10.1007/s00405-016-4313-x
- Masieri S, Cavaliere C, Begvarfaj E, et al. Effects of omalizumab therapy on allergic rhinitis: a pilot study. Eur Rev Med Pharmacol Sci. 2016;20(24):5249–5255.
Supplementary files
![](/img/style/loading.gif)